NCT04312308 is a clinical trial of Sample collection in Non Small Cell Lung Cancer, sponsored by Yonsei University.

Who is sponsoring NCT04312308?

NCT04312308 is sponsored by Yonsei University.

What drugs are being tested in NCT04312308?

Interventions in NCT04312308: Sample collection.

What condition does NCT04312308 study?

NCT04312308 studies Non Small Cell Lung Cancer.

Is NCT04312308 still recruiting?

NCT04312308 is currently completed. Last updated 6 February 2026.

Last reviewed 2026-02-06 · How we verify

NCT04312308

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients

Completed Last updated 6 February 2026

What this trial tests

trial testing Sample collection in Non Small Cell Lung Cancer in 100 participants. Completed in 26 January 2025.

Timeline

8 April 2020

Primary endpoint
26 January 2025

26 January 2025

Quick facts

Lead sponsor	Yonsei University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	8 April 2020
Primary completion	26 January 2025
Estimated completion	26 January 2025
Sites	1 location across South Korea

Drugs / interventions tested

Sample collection — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Yonsei University

Who can join

20 and older, female only, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aimed to elucidate predictive immune related biomarker to the responsiveness to the PD-L1 blockade and evaluate the dynamics of immune cells in peripheral blood from NSCLC patients during atezolizumab treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review).
Vivarelli S, Falzone L, Leonardi GC, Salmeri M, et al · · 2021 · cited 21× · PMID 34396439 · DOI 10.3892/ijo.2021.5255
Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy.
Zhou W, Huang Z, Wu Z, Tang M, et al · · 2025 · cited 3× · PMID 40857744 · DOI 10.1042/ebc20253017

Verify or expand the search:

Other trials of Sample collection

Trials testing the same drug.

NCT06634160 — Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozyg · recruiting
NCT04894370 — Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma · Phase 2 · recruiting
NCT06820151 — Exploring the Landscape of Injury and Repair in the Human Oesophagus · enrolling by invitation
NCT05937815 — Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor · NA · unknown
NCT05462366 — Omics Sequencing of Specimen Derived From Mother-Infant-Pairs · recruiting

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04312308 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 6 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04312308.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing